{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:33:44Z","timestamp":1771266824964,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jiac.2025.102878","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:46:12Z","timestamp":1764175572000},"page":"102878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-biomarker integration in predicting bedaquiline treatment response among diabetic MDR-TB patients"],"prefix":"10.1016","volume":"32","author":[{"given":"Liqing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jiac.2025.102878_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12879-024-09079-5","article-title":"Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019","volume":"24","author":"Lv","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2025.102878_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00180-19","article-title":"The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2025.102878_bib3","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/IDR.S365394","article-title":"Multidrug-resistant tuberculosis treatment outcome and associated factors at the university of gondar comprehensive specialized hospital: a ten-year retrospective study","author":"Belachew","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2025.102878_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107140","article-title":"Tuberculosis and diabetes mellitus: the complexity of the comorbid interactions","author":"Boadu","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102878_bib5","article-title":"Tuberculosis and comorbidities: treatment challenges in patients with comorbid diabetes mellitus and depression","volume":"9","author":"C\u00e1ceres","year":"2022","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jiac.2025.102878_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1244450","article-title":"The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis","volume":"11","author":"Rehman","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.jiac.2025.102878_bib7","series-title":"Diabetes mellitus and tuberculosis","author":"Krishna","year":"2021"},{"key":"10.1016\/j.jiac.2025.102878_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/0127724344318310241018113206","article-title":"Bedaquiline delivery innovations: a review on advancing MDR-TB treatment strategies","volume":"20","author":"Ahmad","year":"2025","journal-title":"Recent Advan Anti-Infective Drug Discovery"},{"issue":"8","key":"10.1016\/j.jiac.2025.102878_bib9","article-title":"Bedaquiline: a novel diarylquinoline for multidrug-resistant pulmonary tuberculosis","volume":"14","author":"Deshkar","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jiac.2025.102878_bib10","first-page":"1","article-title":"Population pharmacokinetics of bedaquiline: a systematic review","author":"Jin","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.jiac.2025.102878_bib11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/antiox10071143","article-title":"Metabolic changes and oxidative stress in diabetic kidney disease","volume":"10","author":"Sakashita","year":"2021","journal-title":"Antioxidants"},{"issue":"10","key":"10.1016\/j.jiac.2025.102878_bib12","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1021\/acsomega.0c06165","article-title":"Effect of disease state on the pharmacokinetics of bedaquiline in renal-impaired and diabetic rats","volume":"6","author":"Gour","year":"2021","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.jiac.2025.102878_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01859-21","article-title":"Biomarkers that correlate with active pulmonary tuberculosis treatment response: a systematic review and meta-analysis","volume":"60","author":"Zimmer","year":"2022","journal-title":"J Clin Microbiol"},{"issue":"1","key":"10.1016\/j.jiac.2025.102878_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2386030","article-title":"Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: a review","volume":"56","author":"Leo","year":"2024","journal-title":"Ann Med"},{"issue":"12","key":"10.1016\/j.jiac.2025.102878_bib15","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/antibiotics13121216","article-title":"Identification of factors determining patterns of serum C-Reactive protein level reduction in response to treatment initiation in patients with drug-susceptible pulmonary tuberculosis","volume":"13","author":"Kivrane","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.jiac.2025.102878_bib16","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2023.03.013","article-title":"Update of drug-resistant tuberculosis treatment guidelines: a turning point","volume":"130","author":"Vanino","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.jiac.2025.102878_bib17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5588\/ijtld.22.0263","article-title":"WHO drug-resistant TB guidelines 2022: what is new","volume":"26","author":"Migliori","year":"2022","journal-title":"Int J Tubercul Lung Dis"},{"issue":"9","key":"10.1016\/j.jiac.2025.102878_bib18","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiac.2025.102878_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115281","article-title":"Pharmacokinetics of obese adults: not only an increase in weight","volume":"166","author":"Gouju","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jiac.2025.102878_bib20","series-title":"Open forum infectious diseases","first-page":"ofy253","article-title":"Evaluation of tuberculosis treatment response with serial C-reactive protein measurements","author":"Wilson","year":"2018"},{"key":"10.1016\/j.jiac.2025.102878_bib21","article-title":"The role of C-Reactive protein as an inflammatory marker to predict prolonged QTc interval in rifampicin-resistant tuberculosis patients: a case-control study","volume":"70","author":"Kusmiati","year":"2021","journal-title":"Ann Med Surg"},{"issue":"13","key":"10.1016\/j.jiac.2025.102878_bib22","doi-asserted-by":"crossref","first-page":"7105","DOI":"10.3390\/ijms25137105","article-title":"Pathology of diabetes-induced immune dysfunction","volume":"25","author":"Alexander","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.jiac.2025.102878_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/507543","article-title":"Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes","volume":"43","author":"Nijland","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jiac.2025.102878_bib24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/biomedicines8070182","article-title":"Endothelial dysfunction in diabetes","volume":"8","author":"Takeda","year":"2020","journal-title":"Biomedicines"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:07:16Z","timestamp":1767859636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1341321X25002752"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102878","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-biomarker integration in predicting bedaquiline treatment response among diabetic MDR-TB patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102878"}}